Page last updated: 2024-11-05

poloxalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Poloxalene: A copolymer of polyethylene and polypropylene ether glycol. It is a non-ionic polyol surface-active agent used medically as a fecal softener and in cattle for prevention of bloat. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pluronic : A triblock copolymer composed of a central hydrophobic chain of poly(propylene oxide) flanked by two hydrophilic chains of poly(ethylene oxide). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24751
CHEBI ID32026
SCHEMBL ID11737
MeSH IDM0017132

Synonyms (152)

Synonym
thanol e 4003
2-methyloxirane; oxirane
106392-12-5
monolan pb
magcyl
pluronic f 88
teric pe40
velvetol oe 2nt1
rokopol 30p9
sk & f 18,667
slovanik 630
pronon 204
pronon 201
pronon 208
pluronic f 98
pluronic l 64
laprol 1502
pluronic p-75
emkalyx l 101
emkalyx l101
pluronic l 122
pluronic f
pluronic l64(mw 2900)
therabloat
monolan 8000e80
pluronic l-101
pluronic l 61
nixolen sl 19
hydrowet
pluronic l
pluronic l 92
epon 420
epan 485
pluronic l 35
niax 16-46
nsc-63908
pluronic f 68lf
proxanol 158
slovanik 660
rc 102
pluronic p 75
berol tvm 370
pluronic l 101
propylen m 12
pluronic l 121
epan 750
poloxalkol
pluronic l-81
unilube 50mb26x
tvm 370
slovanik
pluronic f 125
pluronic
m 90/20
pluronic f-68
pluronic p 85
unilube 50mb168x
proksanol
voranol p 2001
pluronic 31r2
epan 785
lg 56
bsp 5000
pluronic l44
pluronic 10r8
rokopol 30p
tergitol monionic xh
component of casakol
sk&f 18,667
teric pe60
teric pe70
pluronic l 44
poloxalene
pluronic p-65
pluronic l62(mw 2500)
pluronic c 121
pluronic f 38
pluronic f 108
75h90000
ppg diol 3000eo
pronon 102
proxanol 228
teric pe 62
n 480
pluronic l 31
f-108
pluronic f 127
wyandotte 7135
pluronic-68
poloxamer 407
pluronic f86
9003-11-6
emkalyx ep 64
tergitol xh (nonionic)
nsc63908
poloxamer 188
pluriol pe 6810
poloxamer 182lf
pluronic l 62
poloxamer 108
oligoether l-1502-2-30
plonon 201
epan 710
eban 710
tergitol xh
regulaid
pluronic f 87
proxanol
nissan pronon 201
pluracol v
pluronic f 68
teric pe 61
pluronic l 24
tsl 431
synperonic pe 30/40
newpol pe-88
rokopol 16p
pluronic p 104
ws 661
pronon 104
pluronic f87-a7850
supronic b 75
pluriol pe
pluronic l 68
pluronic p
poloxalene l64
supronic e 400
plonon 204
bloat guard
genapol pf 10
niax lg 56
poloxamer 331
poloxamer (nf)
lutrol f (tn)
D01941
AKOS015912614
SCHEMBL11737
pluronic l122
ethylene oxide propylene oxide
adeka pluronic f-108
propylene oxide ethylene oxide
RVGRUAULSDPKGF-UHFFFAOYSA-N
oxirane-propylene oxide
D10680
vepoloxamer (usan)
691397-13-4
peg-ppg-peg
CHEBI:32026
DB11451
2-methyloxirane;oxirane
tergitol(tm)xh(nonionic)
oxirane, methyl-, polymer with oxiraneother ca index names:oxirane, polymer with methyloxirane

Research Excerpts

Actions

ExcerptReferenceRelevance
"Poloxalene did not increase drug absorption, but higher concentrations caused a decrease in absorption due to micellar entrapments of the drug molecules."( Effect of surfactants on absorption through membranes III: effects of dioctyl sodium sulfosuccinate and poloxalene on absorption of a poorly absorbable drug, phenolsulfonphthalein, in rats.
Canaham, DH; Gouda, MW; Malik, SN, 1975
)
1.19

Toxicity

ExcerptReferenceRelevance
" L61 was toxic to the cells with or without drug (viability<3."( Enhancement of carboplatin toxicity by Pluronic block copolymers.
Exner, AA; Krupka, TM; Scherrer, K; Teets, JM, 2005
)
0.33
" No study product-related serious adverse events were reported."( A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
Bergeron, MG; Domingo, MC; Fokoua, S; Giguere, JF; Mâsse, B; Mbopi-Keou, FX; Mbu, ER; Mwatha, A; Nkele, NN; Omar, RF; Piret, J; Trottier, S; Tsague, L; Zekeng, L, 2009
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
") infusion to healthy male volunteers and to determine the pharmacokinetic profile of poloxamer 188."( Pharmacokinetics of RheothRx injection in healthy male volunteers.
Jewell, RC; Khor, SP; Kisor, DF; LaCroix, KA; Wargin, WA, 1997
)
0.3
" The half-life of menatetrenone in plasma when oxyethylene units made up less than 30% of the Pluronic (SO/PL101 and SO/PP103) was similar to that for SO/egg yolk phosphatides (SO/EYP), but longer than that when oxyethylene units composed more than 40% of the Pluronic (SO/PP104 and SO/PF108, by 3- and 10-fold, respectively)."( Effect of oxyethylene numbers on the pharmacokinetics of menatetrenone incorporated in oil-in-water lipid emulsions prepared with polyoxyethylene-polyoxypropylene block copolymers and soybean oil in rats.
Iwakawa, S; Kawaguchi, Y; Ueda, K, 2008
)
0.35
" However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h)."( Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies.
Basalious, EB; Shamma, RN, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The potential of these alternative formulations for increasing the ocular bioavailability of forskolin is discussed."( Preparation and evaluation in rabbits of topical solutions containing forskolin.
Burgalassi, S; Giannaccini, B; Saettone, MF, 1989
)
0.28
" The bioavailability of oleaginous base and water-soluble base (polyethylene glycol 4000) were 44."( Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit.
Itoh, S; Morishita, N; Sawanoi, M; Suginaka, A; Tanabe, K; Yamazaki, M, 1987
)
0.27
" The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution."( Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24).
Buri, P; Martenet, M; Wüthrich, P, 1994
)
0.29
" Surfactants have been suggested to enhance the bioavailability of hydrophobic compounds, but both negative and positive effects of surfactants on biodegradation have been reported in the literature."( Quantifying the biodegradation of phenanthrene by Pseudomonas stutzeri P16 in the presence of a nonionic surfactant.
Aitken, MD; Grimberg, SJ; Stringfellow, WT, 1996
)
0.29
" The release profiles obtained can be of value when an improvement in the bioavailability of the drug is desired."( Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres.
Couarraze, G; Duchêne, D; Lemos-Senna, E; Lesieur, S; Puisieux, F; Wouessidjewe, D, 1998
)
0.3
" This in vivo study showed that polymeric P-gp inhibitors and especially the delivery system based on thiolated chitosan significantly increased the oral bioavailability of P-gp substrate Rho-123."( In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein.
Bernkop-Schnürch, A; Föger, F; Hoyer, H; Kafedjiiski, K; Thaurer, M, 2006
)
0.33
" Interestingly, the concurrent biodegradation of the surfactants reduced their effective concentrations for micelle formation and, hence, contribute to the higher bioavailability of phenanthrene by gradually releasing phenanthrene molecules into the aqueous phase."( Effect of nonionic surfactants on biodegradation of phenanthrene by a marine bacteria of Neptunomonas naphthovorans.
Chen, BH; Li, JL, 2009
)
0.35
" In vivo pharmacokinetic study in rats showed that the polymeric micelles significantly enhanced the bioavailability of PTX (∼3 fold) than Taxol."( Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors.
Chen, Y; Fang, X; Sha, X; Shi, Y; Ye, J; Zhang, W, 2011
)
0.37
" Collectively, these results obtained from the present study demonstrated that P123 and F127 were capable of inhibiting the intestinal P-gp activity, but had little or no effect on intestinal cytochrome P450 3A activity, indicating that P123 and F127 can potentially be used as pharmaceutical ingredients to improve the oral bioavailability of coadministered P-gp substrates via P-gp efflux pump inhibition."( Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism.
Guan, Y; Huang, J; Li, G; Qiu, J; Si, L; Xu, J; Zuo, L, 2011
)
0.37
" By using transporter inhibitors, the aim of this trial was to assess the possibility of increasing drug bioavailability in the host in an attempt to improve treatment efficacy."( Influence of Pluronic 85 and ketoconazole on disposition and efficacy of ivermectin in sheep infected with a multiple resistant Haemonchus contortus isolate.
Alvinerie, M; Bartley, DJ; Bartley, Y; Devin, L; Dupuy, J; Jackson, F; Lespine, A; Menez, C; Morrison, AA; Sutra, JF, 2012
)
0.38
" There is a recent interest to use pluronic for improving the solubility and bioavailability of these drugs."( A fluorescence study on the interaction of telmisartan in triblock polymers pluronic P123 and F127.
Mishra, AK; Mohanty, ME; Rao, VJ, 2014
)
0.4
"6-fold enhancement in its oral bioavailability in rats."( Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
Deng, J; Li, WG; Ning, Q; Yu, DN; Zhou, Y, 2014
)
0.4
" This method seems to effectively enhance the bioavailability of breviscapine in rats."( Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
Deng, J; Li, WG; Ning, Q; Yu, DN; Zhou, Y, 2014
)
0.4
" However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h)."( Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies.
Basalious, EB; Shamma, RN, 2015
)
0.42
" The SD prepared with F68 alone significantly enhanced the dissolution but not intestinal permeation of docetaxel, leading to only limited enhancement of oral bioavailability (1."( Poloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailability.
Kim, DD; Song, CK; Yoon, IS, 2016
)
0.43
"This study aimed to develop a new stable nanoformulation of silymarin (SM) with optimum enhanced oral bioavailability and to evaluate its effect as well as mechanism of action as a superior antidiabetic agent over native SM using streptozotocin-induced diabetic rats."( A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes.
Eissa, LA; El Gayar, AM; El-Far, YM; El-Sherbiny, IM; Gabr, MM; Zakaria, MM, 2016
)
0.43
" In addition, SMnp was found to be a more efficient agent over SM in the management of diabetes and its associated complications due to its superior bioavailability in vivo, and the controlled release profile of SM."( A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes.
Eissa, LA; El Gayar, AM; El-Far, YM; El-Sherbiny, IM; Gabr, MM; Zakaria, MM, 2016
)
0.43
" Its poor aqueous solubility and low bioavailability are often overcome by using micelles and vesicles as its carriers."( Heat-induced solubilization of curcumin in kinetically stable pluronic P123 micelles and vesicles: An exploit of slow dynamics of the micellar restructuring processes in the aqueous pluronic system.
Aswal, VK; Ballal, A; Barick, KC; Dutta, B; Ganguly, R; Hassan, PA; Kumar, S; Kunwar, A, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" In evaluating this model, dose-response studies were conducted with lipopolysaccharide when a) it was administered intraperitoneally in saline or in Pluronic F 127 liquid, and b) it was administered intravenously to mice that had been pretreated with saline or Pluronic F 127 liquid."( Pluronic F 127 liquid sensitizes mice to low doses of Escherichia coli lipopolysaccharide.
Dejoy, SQ; Desai, NR; Gibbons, JJ; Kerwar, SS; Oronsky, AL; Pickett, WC; Torley, LW, 1992
)
0.28
" The application of 50 mg of the 1% ketoprofen gel on the rat hind paw at various time intervals from 0 to 24 h prior to the carrageenan injection significantly inhibited edema formation in all groups of dosed rats."( Anti-inflammatory activity of ketoprofen gel on carrageenan-induced paw edema in rats.
Chi, SC; Jun, HW, 1990
)
0.28
" Contact with different materials in dosing devices, other design-related factors and motion appear to be chemically more detrimental than storage in glass vials at the same temperature."( Chemical stability of insulin in a delivery system environment.
Grau, U, 1985
)
0.27
" In spite of this higher dosage we failed to mobilize 131 J labelled fat, embolized into the lungs of the animals."( [Study of principles in pathogenesis and therapy of fat embolism. IV. In vivo studies of drug-induced mobilization of embolized lung fat].
Bergmann, H; Gottlob, R; Kokoschka, R; Porschinski, K; Saghir, F; Sogukoglu, T, 1982
)
0.26
" Because of changes in drug dosage necessitated by the occurrence of acute renal dysfunction, the trial was stopped."( Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group.
Cerqueira, MD; Hallstrom, AP; Martin, JS; Maynard, C; Paris, JA; Swenson, R; Weaver, WD, 1998
)
0.3
"Poly(ethylene oxide)-b-poly(propylene oxide)-b-(polyethylene oxide)-g-poly(acrylic acid), a graft-comb copolymer of Pluronic 127 and poly(acrylic acid) (Pluronic-PAA), was explored as an excipient for tablet dosage form of camptothecin (CPT)."( Controlled release camptothecin tablets based on pluronic and poly(acrylic acid) copolymer. Effect of fabrication technique on drug stability, tablet structure, and release mode.
Alvarez-Lorenzo, C; Barreiro-Iglesias, R; Bromberg, L; Concheiro, A; Hatton, TA, 2007
)
0.34
" Based on the numerous advantages of oral administration, such as cost-effectiveness, flexible and accommodated dosing regimen, and improved compliance for patients, the ST-P123-MMs system would be evaluated as oral delivery vehicle of BC."( In vitro and in vivo study of Baicalin-loaded mixed micelles for oral delivery.
Jiao, Y; Liu, J; Yang, X; Zhai, G; Zhang, H; Zhao, L, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (615)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990148 (24.07)18.7374
1990's219 (35.61)18.2507
2000's87 (14.15)29.6817
2010's146 (23.74)24.3611
2020's15 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.15 (24.57)
Research Supply Index6.53 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index70.70 (26.88)
Search Engine Supply Index2.14 (0.95)

This Compound (42.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (3.18%)5.53%
Reviews16 (2.42%)6.00%
Case Studies3 (0.45%)4.05%
Observational0 (0.00%)0.25%
Other620 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]